Sabine van Rijt
Overview
Explore the profile of Sabine van Rijt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smeets L, Sengun E, Trayford C, van Cranenbroek B, de Jonge M, Dallaglio K, et al.
ACS Appl Bio Mater
. 2025 Feb;
8(2):1511-1523.
PMID: 39900538
Mesenchymal stem cells (MSCs) have demonstrated promising therapeutic potential across a wide range of diseases including (multi) organ injury in neonates. Despite the reported preclinical successes of MSC therapy, a...
2.
He L, Javid Anbardan Z, Habibovic P, van Rijt S
ACS Appl Nano Mater
. 2024 Nov;
7(22):25400-25411.
PMID: 39606122
Doxorubicin (Dox) is a promising anticancer chemotherapeutic, which has been widely investigated in osteosarcoma (OS) treatment. However, there are several disadvantages regarding its clinical use. Specifically, Dox has low specificity...
3.
Zengin A, Hafeez S, Habibovic P, Baker M, van Rijt S
J Mater Chem B
. 2024 Nov;
12(48):12577-12588.
PMID: 39508381
The extracellular matrix (ECM) is a dynamic environment that is primarily built up from fibrous proteins (, elastins, fibronectins, collagens, and laminins) and plays a vital role in tissue regeneration...
4.
Trayford C, van Rijt S
Biomater Sci
. 2024 Oct;
12(21):5450-5467.
PMID: 39371000
Over the last 20 years, mesoporous silica nanoparticles (MSNs) have drawn considerable attention in the biomedical field due to their large surface area, porous network, biocompatibility, and abundant modification possibilities....
5.
Trayford C, Ibrahim D, van Rijt S
Int J Nanomedicine
. 2024 Sep;
19:9741-9755.
PMID: 39329032
Introduction: Oligonucleotide (ON) therapy is a promising treatment for a wide range of complex genetic disorders, but inefficient intracellular ON delivery has hindered clinical translation. Hollow silica nanoparticles (HSN) hold...
6.
Zhang X, van Veen S, Hadavi D, Zhao Y, Mohren R, Habibovic P, et al.
Small
. 2024 May;
20(37):e2311402.
PMID: 38757547
The native extracellular matrix (ECM) undergoes constant remodeling, where adhesive ligand presentation changes over time and in space to control stem cell function. As such, it is of interest to...
7.
Fois M, Zengin A, Song K, Giselbrecht S, Habibovic P, Truckenmuller R, et al.
ACS Appl Mater Interfaces
. 2024 Apr;
16(14):17347-17360.
PMID: 38561903
Three-dimensional (3D) cell assemblies, such as multicellular spheroids, can be powerful biological tools to closely mimic the complexity of cell-cell and cell-matrix interactions in a native-like microenvironment. However, potential applications...
8.
Nottelet B, Buwalda S, van Nostrum C, Zhao X, Deng C, Zhong Z, et al.
JPhys Mater
. 2023 Dec;
7(1):012502.
PMID: 38144214
This Roadmap on drug delivery aims to cover some of the most recent advances in the field of materials for drug delivery systems (DDSs) and emphasizes the role that multifunctional...
9.
Trayford C, Wilhalm A, Habibovic P, Smeets H, van Tienen F, van Rijt S
Discov Nano
. 2023 Dec;
18(1):161.
PMID: 38127184
Mutations in nuclear and mitochondrial genes are responsible for severe chronic disorders such as mitochondrial myopathies. Gene therapy using antisense oligonucleotides is a promising strategy to treat mitochondrial DNA (mtDNA)...
10.
Zengin A, Teixeira F, Feliciano T, Habibovic P, Mota C, Baker M, et al.
Biomater Adv
. 2023 Oct;
154:213647.
PMID: 37839298
The development of suitable bioinks with high printability, mechanical strength, biodegradability, and biocompatibility is a key challenge for the clinical translation of 3D constructs produced with bioprinting technologies. In this...